Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Triple Negative Breast Cancer: early-phase trial registry
68 of 119 indexed Triple Negative Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #105 of 28,707 conditions by registered trial count.
119 US clinical trials · 68 currently recruiting · #105 of 28,707 conditions by registered trial count
Triple Negative Breast Cancer: 119 US clinical trials tracked, 68 recruiting.
Triple Negative Breast Cancer is the subject of 119 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 6 of these trials.
Enrollment posture brief
Registry condition triple-negative-breast-cancer
OPEN 68 | RECR 57% | LATE 8 | EARLY 98 | RANK #105 | SPON 6
Volume-matched condition peers
Nearest open-share peer: ACL (57% recruiting · 7 trials)
Triple Negative Breast Cancer lists 68 open slots (57% of 119 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Triple Negative Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Triple Negative Breast Cancer is recruiting above its size-band peers.
68 of 119 indexed trials (57.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Triple Negative Breast Cancer trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 6 of 119 trials (5%). 91 distinct sponsors appear on at least one study for this condition label.
-
Typical Triple Negative Breast Cancer enrolment sits around 77 participants.
Median target enrolment is 77 among the 119 trials that report a genuine target (sentinel values excluded). 67 of those (56.3%) plan for fewer than 100 participants.
-
Triple Negative Breast Cancer research is mostly interventional.
112 interventional and 7 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
119 total, page 1 of 3
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Persephone Biosciences
NCT04638751
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Merck Sharp & Dohme
NCT06393374
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
NCT05633654
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
VastBiome
NCT05037825
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT05579366
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Jina Pharmaceuticals
NCT03671044
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
AbbVie
NCT05005403
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18
NCT04787042
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
NCT07318805
Sacituzumab Govitecan In TNBC
Massachusetts General Hospital
NCT04230109
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
NCT07046923
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Brigham and Women's Hospital
NCT04030507
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
NCT06134375
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics
NCT05902988
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT05020860
Study of Screening Brain MRIs in Stage IV Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05115474
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine
NCT06022029
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Kathy Miller
NCT05846789
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Novartis Pharmaceuticals
NCT06562192
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
Yale University
NCT07066189
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Memorial Sloan Kettering Cancer Center
NCT03808337
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
University of Kansas Medical Center
NCT05645380
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT05783622
PRE-I-SPY Phase I/Ib Oncology Platform Program
QuantumLeap Healthcare Collaborative
NCT05868226
A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics
NCT05086692
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Dana-Farber Cancer Institute
NCT04468061
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Gilead Sciences
NCT06926920
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics
NCT06399757
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Accent Therapeutics
NCT06799065
Cardiac Outcomes With Near-Complete Estrogen Deprivation
Duke University
NCT05309655
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05528133
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
A&G Pharmaceutical
NCT05627960
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT06150664
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
NCT07064018
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07115043
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Mabwell (Shanghai) Bioscience Co.
NCT06908928
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
ProDa BioTech
NCT06460298
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
Wake Forest University Health Sciences
NCT04677816
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
Medical University of South Carolina
NCT06845319
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
NCT06347068
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University
NCT04768426
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
NCT04434040
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 70 |
| Phase 2 | 28 |
| Phase 3 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Triple Negative Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Triple Negative Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Triple Negative Breast Cancer page
119 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 Triple Negative Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Triple Negative Breast Cancer trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Triple Negative Breast Cancer condition card totals 119 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.